Alnylam announces fda approval of amvuttra® (vutrisiran), the first rnai therapeutic to reduce cardiovascular death, hospitalizations and urgent heart failure visits in adults with attr amyloidosis with cardiomyopathy (attr-cm)

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the u.s. food and drug administration (fda) approval of the supplemental new drug application (snda) for its rnai therapeutic, amvuttra® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (attr-cm) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failu.
ALNY Ratings Summary
ALNY Quant Ranking